Table 2.
Prevalence of different lesions according to the per-protocol analysis
| Pathological diagnosis | Cases N (%) | High-risk areas N (%) | Non-high-risk areas N (%) | P value |
|---|---|---|---|---|
| All subjects under endoscopy | 37,922 | 26,633 | 11,289 | |
| Esophagus | ||||
| Esophagitis | 4349 (11.5) | 4173 (15.7) | 176 (1.6) | < 0.001 |
| Mild/moderate dysplasia, or dysplasia, NOS | 1692 (4.5) | 1600 (6.0) | 92 (0.8) | < 0.001 |
| Severe dysplasia/EC in situ | 195 (0.5) | 187 (0.7) | 8 (0.1) | < 0.001 |
| EC | 59 (0.2) | 52 (0.2) | 7 (0.1) | 0.003 |
| Positive esophageal lesions | 254 (0.7) | 239 (0.9) | 15 (0.1) | < 0.001 |
| Stomach | ||||
| Atrophic gastritis | 5522 (14.6) | 5132 (19.3) | 390 (3.5) | < 0.001 |
| Intestinal metaplasia/low-grade dysplasia | 2977 (7.9) | 2257 (8.5) | 720 (6.4) | < 0.001 |
| High-grade dysplasia | 117 (0.3) | 105 (0.4) | 12 (0.1) | < 0.001 |
| GC | 167 (0.4) | 143 (0.5) | 24 (0.2) | < 0.001 |
| Positive stomach lesions | 284 (0.8) | 248 (0.9) | 36 (0.3) | < 0.001 |
| Positive cases in totala | 528 (1.4) | 478 (1.8) | 50 (0.4) | < 0.001 |
aTen positive cases had advanced lesions both at esophageal and stomach site